Eplerenone
- Generic Name
- Eplerenone
- Brand Names
- Inspra
- Drug Type
- Small Molecule
- Chemical Formula
- C24H30O6
- CAS Number
- 107724-20-9
- Unique Ingredient Identifier
- 6995V82D0B
- Background
Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors.
- Indication
For improvement of survival of stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and clinical evidence of congestive heart failure after an acute myocardial infarction.
- Associated Conditions
- Hypertension, LVEF <40% Congestive heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class II)
- Associated Therapies
- -
Reversing Endothelial and Diastolic Dysfunction and Improving Collagen Turnover in Diastolic Heart Failure
- First Posted Date
- 2006-02-17
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 11
- Registration Number
- NCT00293150
- Locations
- 🇺🇸
The Cleveland Clinic, Cleveland, Ohio, United States
A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Target Recruit Count
- 2743
- Registration Number
- NCT00232180
- Locations
- 🇻🇪
Pfizer Investigational Site, Caracas, Estado Miranda, Venezuela
Treatment of Supine Hypertension in Autonomic Failure
- Conditions
- Hypertension
- Interventions
- Drug: PlaceboDrug: ClonidineDrug: Nitroglycerin transdermalDrug: Dipyridamole/ Aspirin (Aggrenox)Drug: Desmopressin (DDAVP)Drug: SildenafilDrug: NifedipineDrug: HydralazineDrug: HydrochlorothiazideDrug: BosentanDrug: DiltiazemDrug: EplerenoneDrug: guanfacineDietary Supplement: L-arginineDrug: captoprilDrug: carbidopaDrug: losartanDrug: metoprolol tartrateDrug: nebivolol hydrochlorideDrug: prazosin hydrochlorideDrug: tamsulosin hydrochlorideOther: Head-up tilt.Drug: aliskirenOther: Local heat stress
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 152
- Registration Number
- NCT00223717
- Locations
- 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
Aldosterone and Vascular Disease in Diabetes Mellitus
- Conditions
- Diabetes MellitusEndothelial DysfunctionAlbuminuria
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2008-01-03
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT00214825
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia
- Conditions
- Ischemic Heart Disease
- Interventions
- Drug: EplerenoneDrug: Placebo or sugar pill
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2013-10-14
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 70
- Registration Number
- NCT00187889
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
A Study to Evaluate the Efficacy and Safety of Eplerenone in the Treatment of Hypertension in Children.
- Conditions
- Hypertension
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT00147589
- Locations
- 🇿🇦
Pfizer Investigational Site, Cape Town, South Africa
Compare Effectiveness of Eplerenone vs Atenolol in Reversing the Remodelling Resistance Arteries in Subjects With HT
- Conditions
- Hypertension
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2008-04-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 34
- Registration Number
- NCT00147563
- Locations
- 🇨🇦
Pfizer Investigational Site, Montreal, Quebec, Canada
The Long-term Study to Evaluate the Safety of Eplerenone in the Treatment of Hypertension in Children Aged 6 to 16 Years
- Conditions
- Hypertension
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT00147615
- Locations
- 🇷🇺
Pfizer Investigational Site, St. Petersburg, Russian Federation
Effectiveness of Eplerenone to Improve Target Organ Damage in Patients With Resistant Arterial Hypertension
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 85
- Registration Number
- NCT00138944
- Locations
- 🇩🇪
CRC Medical Department IV, Erlangen, Germany
Effects of Eplerenone on Left Ventricular Remodelling Following Heart Attack
- Conditions
- Myocardial Infarction
- First Posted Date
- 2005-08-19
- Last Posted Date
- 2006-04-10
- Lead Sponsor
- NHS Greater Glasgow and Clyde
- Target Recruit Count
- 100
- Registration Number
- NCT00132093
- Locations
- 🇬🇧
Western Infirmary, Glasgow, Scotland, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.